Aug. 11, 2020 9:25 AM ET
- Relief Therapeutics is in advanced clinical trials with their drug RLF-100 which aims to halt COVID-19 and reverse its devastating effects.
- Just-released Compassionate Use results showed stunning results: ventilator-dependent COVID-19 patients with deadly comorbidities coming off the ventilator and returning home in only five days after treatment with RLF-100.
- Relief Therapeutic’s RLF-100 is both easy to manufacture at scale and inexpensive, meaning that success in clinical trials could translate to rapid worldwide production and availability.
- If in-progress clinical trials reflect the Compassionate Use results, RLF-100 will likely garner immediate approval, and shares could go much higher.
Relief Therapeutics Holdings AG (OTCPK:RLFTF) is a Swiss Company that trades on the U.S. OTC Exchange in addition to its Swiss Stock Exchange Listing (RLF). Only a week ago, Relief Therapeutics was trading under .10 per share. It was the rediscovery of the properties of their drug RLF-100, a proprietary synthetic form of Vasoactive Intestinal Polypeptide (VIP) also known as aviptadil, which has led to the justifiable interest in the company.
In a previous article, I described my rationale for following potential Covid-19 therapeutics over potential vaccines, and the progression of the disease from viral to immunologic that has served to categorize the various approaches to fighting Covid-19 and its effects. I won’t repeat that discussion here, as I’m eager to get to the point that Relief Therapeutics’ drug is the most promising that I have encountered to tackle Covid-19 in four months of research.
Click here for the full article: https://seekingalpha.com/article/4367483-relief-therapeutics-discovers-promising-covidminus-19-killer